Abstract: The present invention includes a transient method of delivering a biological agent in a breathable liquid to a lung of a patient. The present invention includes a steady state method of delivering a biological agent in a breathable liquid to a lung of a patient. The steps of both the transient delivery method and the steady state delivery method can be controlled by a servo-control unit. A supplementary biological agent delivery step can be performed in both the transient method of delivering a biological agent and the steady state method of delivering a biological agent.
Type:
Application
Filed:
March 17, 2011
Publication date:
July 7, 2011
Applicant:
Temple University - Of The Commonwealth System of Higher Education
Abstract: Substituted phenol derivatives of Formula (I) are useful as antiproliferative agents including, for example, anticancer agents, and as radioprotective and chemoprotective agents.
Type:
Grant
Filed:
March 15, 2005
Date of Patent:
April 26, 2011
Assignees:
Temple University - Of The Commonwealth System of Higher Education, Onconova Therapeutics Inc.
Inventors:
E. Premkumar Reddy, M. V. Ramana Reddy, Stanley C. Bell
Abstract: Methods and apparatus for non-collinear optical parametric ampliffication (NOPA) are provided. Broadband phase matching is achieved with a non-collinear geometry and a divergent signal seed to provide bandwidth gain. A chirp may be introduced into the pump pulse such that the white light seed is amplified in a broad spectral region.
Type:
Application
Filed:
February 27, 2009
Publication date:
December 23, 2010
Applicant:
Temple University of the Commonwealth System of Higher Education
Abstract: Methods and compositions are provided for treating myelodysplastic syndrome and acute myeloid leukemia, wherein the composition comprises at least one compound according to Formula I: wherein R1 is selected from the group consisting of —NH2, —NH—CH2—CO2H, —NH—CH(CH3)—CO2H, and —NH—C(CH3)2—CO2H, or a pharmaceutically acceptable salt of such a compound; and a DNA methyltransferase inhibitor, or a pharmaceutically acceptable salt thereof.
Type:
Application
Filed:
August 30, 2006
Publication date:
December 2, 2010
Applicant:
TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Inventors:
E. Premkumar Reddy, M.V. Ramana Reddy, James F. Holland, Lewis R. Silverman, Svetlana Zinzar
Abstract: The invention provides a method for detecting CD163+/CD16+ cell population in peripheral blood mononuclear cells in a biological sample from a subject infected with HIV-1 which comprises contacting the biological sample with an anti-CD163 antibody, so that levels of CD163+/CD16+ peripheral blood mononuclear cells in the biological sample can be quantified.
Type:
Application
Filed:
May 25, 2007
Publication date:
November 18, 2010
Applicant:
Temple University-of the Commonwealth System of Higher Education
Abstract: This invention provides constructs comprising a targeting member immobilized on a detectable particulate, in which binding of the targeting member to a target structure on a surface of a cancer cell triggers internalization of the construct. Such constructs can be used to identify or monitor cancer cells in cell cultures or in a tissue. Such construct can also be used to kill or prevent growth of cancer cells in vivo. Also included in the invention are methods for killing or preventing growth of cancer cells in vivo.
Type:
Application
Filed:
May 10, 2010
Publication date:
November 11, 2010
Applicant:
TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Abstract: A method of controlling obesity by injecting bio-compatible bulking material into the pyloric sphincter area of the stomach. The injection of this material bulks the pyloric sphincter, retarding stomach emptying and producing a feeling of satiation in the patient. The method may be supplemental and augmented by inducing flacid paralysis of the stomach by injecting botulinum toxin into the muscle tissue of the antrum or fundus of the stomach.
Type:
Application
Filed:
September 25, 2009
Publication date:
August 12, 2010
Applicant:
Temple University-Of the Commonwealth System of Higher Education
Abstract: ??-Unsaturated sulfoxides of Formula I: are useful as antiproliferative agents including, for example, anticancer agents, and as radioprotective and chemoprotective agents.
Type:
Grant
Filed:
November 8, 2004
Date of Patent:
June 29, 2010
Assignee:
Temple University - Of The Commonwealth System of Higher Education
Inventors:
E. Premkumar Reddy, M. V. Ramana Reddy, Stanley C. Bell
Abstract: A method of controlling obesity by physically narrowing the lumen of the pylorus One embodiment includes injection of a bio-compatible bulking or stiffening material into the pyloric sphincter area of the stomach. The injection of this material bulks the pyloric sphincter, narrowing the lumen, retarding stomach emptying and producing a feeling of satiation in the patient. The method may be practiced or supplemented by cauterization of the pyloric sphincter or by suturing the sphincter to narrow the same and may be augmented by inducing flacid paralysis of the stomach by injecting botulinum toxin into the muscle tissue of the antrum or fundus of the stomach.
Type:
Grant
Filed:
April 29, 2003
Date of Patent:
June 15, 2010
Assignee:
Temple University of the Commonwealth System of Higher Education
Abstract: The invention provides a novel antigen, MPD6, which belongs to the group of cryptic antigens without conventional genomic structure and is encoded by a cryptic open reading frame located in the 3? untranslated region (3?UTR) of myotrophin mRNA. MPD6 elicits IgG antibody responses in a subset of PV patients, as well as patients with chronic myelogenous leukemia and prostate cancer. The translation of MPD6 was mediated by a novel internal ribosome entry site (IRES) upstream of the MPD6 reading frame. Furthermore, the MPD6-IRES mediated translation, but not myotrophin-MPD6 transcription, was significantly upregulated in response to IFN-? stimulation. These findings demonstrate that a novel IRES-mediated mechanism is responsible for the translation of unconventional self-antigen MPD6 in responsive to IFN-? stimulation. The eliciting anti-tumor immune response against unconventional antigen MPD6 in patients with myeloproliferative diseases indicates MPD6 as a target of novel immunotherapy.
Type:
Application
Filed:
August 16, 2007
Publication date:
June 3, 2010
Applicant:
Temple University - of the Commonwealth System of Higher Education
Abstract: An adjustable suture assembly is provided that may be employed in various surgical procedures to draw and/or hold tissue and/or muscle together. The suture assembly may include a suture lock or tensioner that is adjustably securable to two or more lengths of suture to provide a surgeon with an ability to maintain tissue or muscle in one secured position and subsequently readjust the suture assembly to maintain the tissue or muscle in a different secured position. The suture assembly may include two or more sutures having an anchor attached to an end of each suture for anchoring the suture to desired tissue or muscle. An endoscopic suturing device is provided to deliver and place two or more sutures in tissue or muscle during a surgical procedure. The suturing device may be configured to carry a plurality of sutures so that multiple sutures can be placed in tissue or muscle during a single intubation of the device.
Type:
Application
Filed:
October 18, 2005
Publication date:
February 11, 2010
Applicant:
TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Abstract: An apparatus (100) for reducing the size of fuel particles injected into a combustion chamber is disclosed. The apparatus includes fuel line (110), a first metallic mesh (114) disposed within the fuel line (110), and a second metallic mesh (112) disposed within the fuel line (110), upstream of the first metallic mesh (114). An electrical supply (130) is electrically coupled to the first metallic mesh (114) and the second metallic mesh (112). Operation of the electrical supply (130) generates an electrical field between the first metallic mesh (114) and the second metallic mesh (112). A fuel injector (120) is disposed at an end of the fuel line (110), downstream from the first metallic mesh (114). Methods of reducing the size of fuel particles, improving gas mileage in a vehicle, increasing power output from a combustion engine, and improving emissions for a combustion engine are also provided.
Type:
Application
Filed:
October 30, 2007
Publication date:
February 4, 2010
Applicant:
Temple University of the Commonwealth System of Higher Education
Inventors:
Rongjia Tao, Ke Huang, Deepika Khilnaney-Chhabria, Edward Kaczanowicz
Abstract: Compounds useful as antiproliferative agents according to formula (I): wherein Ar1, Ar2, Ar3, m and n are as defined herein, salts, antibody conjugates, pharmaceutical compositions, methods of treatment, and synthetic methods are provided.
Type:
Application
Filed:
December 12, 2007
Publication date:
February 4, 2010
Applicant:
TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Abstract: An open-circuit liquid ventilation system includes a reservoir containing a breathable liquid, a patient interface receiving breathable liquid from the reservoir, a pump directing breathable liquid from the reservoir to the patient, a controller for the pump, and a tank for storing used breathable liquid. The system may be passive regarding expired liquid. Alternatively, the system may be active and include a bypass line connected to the pump such that used breathable liquid is drawn from the patient. The patient interface may be adapted to interface a gas ventilation system to facilitate a rapid conversion from gas to liquid ventilation. The system may include sensors monitoring pressure and volume parameters and may include an output displaying information including schematics and real time tracings regarding a ventilation procedure.
Type:
Application
Filed:
January 25, 2008
Publication date:
January 21, 2010
Applicant:
TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Abstract: The protein pRb2/p130 represses expression of the ER-? gene. Blocking pRb2/p130 expression or altering ER-? gene methylation to alter pRb2/p130 complex binding allows transcriptional activity of the ER-? gene to be restored. Detecting and regulating the methylation state of the ER-? gene, optionally together with detecting and regulating pRb2/p130 multimolecular complexes bound to the ER-? gene promoter, allows estrogen-insensitive breast cancer cells to be identified, so that an accurate prognosis can be obtained and an appropriate course of treatment administered. Also, inhibiting pRb2/p130, or altering the methylation pattern of the ER-? gene by targeting DNMT 1 In the pRb2/p 130-E2F4/5-HDAC 1-DNMT1-SUV39H1 complex, allows estrogen-insensitive breast cancer cells to be converted to estrogen-sensitive breast cancer cells. Estrogen-sensitive breast cancer cells which are generally more susceptible to current anti-cancer treatments.
Type:
Grant
Filed:
June 1, 2004
Date of Patent:
December 22, 2009
Assignee:
Temple University of the Commonwealth System of Higher Education
Abstract: The invention provides novel antigens, MPD5, PV13, and PV65, which belongs to the group of cryptic antigens without conventional genomic structure and is encoded by a cryptic open reading frame located in the 3?untranslated region (3?UTR) of myotrophin mRNA. The antigens elicit IgG antibody responses in a subset of PV patients, as well as patients with chronic myelogenous leukemia and prostate cancer. The translation of MPD5, PV13 and PV65 was mediated by a novel internal ribosome entry site (IRES) upstream of the open reading frame. Eliciting anti-tumor immune response against MPD5, PV13 and/or PV65 antigen in patients with myeloproliferative diseases is a novel immunotherapy.
Type:
Application
Filed:
October 26, 2007
Publication date:
December 10, 2009
Applicant:
TEMPLE UNIVERSITY -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Abstract: Methods of treating cancer using compounds according to Formula (I) are disclosed herein, wherein X, X1, X2, Ra, R1, R2, R3, R4, R5, R6, R7, g, M, y, a, b, d, e, V, W, Z and Q are as defined herein.
Type:
Application
Filed:
July 14, 2009
Publication date:
November 12, 2009
Applicants:
Temple University - of The Commonwealth System of Higher Education, Onconova Therapeutics, Inc.
Inventors:
E. Premkumar Reddy, M.V. Ramana Reddy, Stanley C. Bell
Abstract: Compounds of Formula I: wherein R1, R2, M, Q and n are as defined herein, are useful as antiproliferative agents including, for example, as anticancer agents.
Type:
Application
Filed:
June 2, 2006
Publication date:
November 5, 2009
Applicant:
TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Abstract: The growth of normal and abnormally proliferating cells can be inhibited by the introduction of agnoprotein, or biologically active fragments or derivatives of agnoprotein, into the cell in the absence of any other polyoma virus protein or viral replication.
Type:
Grant
Filed:
June 11, 2003
Date of Patent:
November 3, 2009
Assignee:
Temple University - Of The Commonwealth System of Higher Education
Abstract: A method of controlling obesity by injecting bio-compatible bulking material into the pyloric sphincter area of the stomach. The injection of this material bulks the pyloric sphincter, retarding stomach emptying and producing a feeling of satiation in the patient. The method may be supplemental and augmented by inducing flaccid paralysis of the stomach by injecting botulinum toxin into the muscle tissue of the antrum or fundus of the stomach.
Type:
Grant
Filed:
August 9, 2001
Date of Patent:
October 27, 2009
Assignee:
Temple University - Of the Commonwealth System of Higher Education